Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients With No Evidence of Disease Progression After First-Line Platinum-Based Chemotherapy

Targeted Oncology - France
doi 10.1007/s11523-015-0369-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cetuximab and Platinum-Based Chemoradio- Or Chemotherapy of Patients With Epidermal Growth Factor Receptor Expressing Adenoid Cystic Carcinoma: A Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2013English

Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2018English

The Role of Epidermal Growth Factor Receptor (EGFR) in the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients

Bulletin of Siberian Medicine
Molecular Medicine
2020English

Epidermal Growth Factor Receptor (EGFR) in Biliary Tract Cancer

HPB
HepatologyGastroenterology
2016English

Effectiveness and Cost-Effectiveness of Erlotinib Versus Gefitinib in First-Line Treatment of Epidermal Growth Factor Receptor–activating Mutation-Positive Non–small-Cell Lung Cancer Patients in Hong Kong

Hong Kong Medical Journal
Medicine
2013English

Association of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment and EGFR Exon 19 Deletion With Frequency of the T790M Mutation in Non-Small Cell Lung Cancer Patients After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

OncoTargets and Therapy
OncologyPharmacology
2019English

Randomized Phase II Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild‐Type Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Efficacy of Bevacizumab Plus Erlotinib Versus Erlotinib Alone in Advanced Non-Small-Cell Lung Cancer After Failure of Standard First-Line Chemotherapy (BeTa): A Double-Blind, Placebo-Controlled, Phase 3 Trial

The Lancet
Medicine
2011English

Randomized Phase III Trial of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients With Extensive-Disease Small Cell Lung Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy